Evidence map›Paper›PMID 38686954›Full record

ArticleMicrobiology spectrum2024

SARS-CoV-2 cellular and humoral responses in vaccine-naive individuals during the first two waves of COVID-19 infections in the southern region of The Netherlands: a cross-sectional population-based study.

D A T Hanssen, K Arts, W H V Nix, N N B Sweelssen, T T J Welbers, C de Theije, L Wieten, D M E Pagen, S Brinkhues, J Penders and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

D A T HanssenDepartment of Medical Microbiology, Infectious Diseases and Infection Prevention, Maastricht University Medical Center, Maastricht, The Netherlands.ORCID 0000-0003-2401-2703
K ArtsDepartment of Medical Microbiology, Infectious Diseases and Infection Prevention, Maastricht University Medical Center, Maastricht, The Netherlands.
W H V NixDepartment of Medical Microbiology, Infectious Diseases and Infection Prevention, Maastricht University Medical Center, Maastricht, The Netherlands.
N N B SweelssenDepartment of Medical Microbiology, Infectious Diseases and Infection Prevention, Maastricht University Medical Center, Maastricht, The Netherlands.
T T J WelbersDepartment of Medical Microbiology, Infectious Diseases and Infection Prevention, Maastricht University Medical Center, Maastricht, The Netherlands.
C de TheijeBioBank Maastricht UMC+, Maastricht University Medical Center, Maastricht, The Netherlands.
L WietenDepartment of Transplantation Immunology, Maastricht University Medical Center, Maastricht, The Netherlands.
D M E PagenCare and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.
S BrinkhuesDepartment of Knowledge and Innovation, Public Health Service (GGD) South Limburg, Heerlen, The Netherlands.
J PendersDepartment of Medical Microbiology, Infectious Diseases and Infection Prevention, Maastricht University Medical Center, Maastricht, The Netherlands.
N H T M Dukers-MuijrersCare and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.
C J P A HoebeDepartment of Medical Microbiology, Infectious Diseases and Infection Prevention, Maastricht University Medical Center, Maastricht, The Netherlands.
P H M SavelkoulDepartment of Medical Microbiology, Infectious Diseases and Infection Prevention, Maastricht University Medical Center, Maastricht, The Netherlands.
I H M van LooDepartment of Medical Microbiology, Infectious Diseases and Infection Prevention, Maastricht University Medical Center, Maastricht, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the emergence of highly transmissible variants of concern, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) still poses a global threat of coronavirus disease 2019 (COVID-19) resurgence. Cellular responses to novel variants are more robustly maintained than humoral responses, and therefore, cellular responses are of interest in assessing immune protection against severe disease in the population. We aimed to assess cellular responses to SARS-CoV-2 at the population level. IFN IMPORTANCE: Data on adaptive cellular immunity are of interest to define immune protection against severe acute respiratory syndrome coronavirus 2 in a population, which is important for decision-making on booster-vaccination strategies. This study provides data on associations between participant characteristics and cellular immune responses in vaccine-naive individuals with different humoral responses.

Indexed as

Antibodies, ViralCOVID-19Immunity, CellularImmunity, HumoralInterferon-gammaSARS-CoV-2AdultAgedCOVID-19 VaccinesCross-Sectional StudiesEnzyme-Linked Immunospot AssayFemaleHumansImmunoglobulin GImmunoglobulin MMaleAntibodies, ViralCOVID-19 VaccinesImmunoglobulin GImmunoglobulin MInterferon-gammaSpike Glycoprotein, Coronavirusantibody responsecellular immunityELISpotIFNγ responseperipheral blood mononuclear cellSARS-CoV-2

Identifiers

PMID38686954
PMCPMC11237656

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.